Zantac/Ranitidine Litigation Spotlight

Zantac, and its generic form – ranitidine, have been on the market for decades, supposedly helping people with heartburn, peptic ulcer disease, and other gastrointestinal issues. Now, however, this seemingly helpful medication has been linked to cancers throughout the digestive system. Let’s take a look at how this extremely common medication became the next pharmaceutical litigation.

Ranitidine was discovered in 1976, and came into commercial use in 1981, becoming the world’s best-selling prescription drug before the end of the decade. Hundreds of millions of people all over the world have used Zantac/ranitidine to treat their stomach problems, never suspecting that they may be putting themselves at risk. Earlier this month, the FDA released a statement on “new testing results, including low levels of impurities in ranitidine drugs” that laid out their findings. The FDA detected small amounts of the toxic chemical NDMA in ranitidine drugs, and left open the possibility that ranitidine actually induces the body to make NDMA. According to the EPA, NDMA is a probable human carcinogen and is toxic to the liver and other organs.

Here is the list of cancers we believe to be linked to ranitidine:

  • Stomach cancer
  • Esophageal cancer
  • Liver cancer
  • Kidney (renal) cancer
  • Colorectal cancer
  • Gallbladder cancer
  • Throat cancer
  • Bladder cancer
  • Pancreatic cancer
  • Appendix cancer
  • Cecum cancer
  • Mouth cancer
  • Small intestine cancer
  • Large intestine cancer
  • Anal cancer

According to the research that we have, the minimum amount of usage in order to be linked to various cancers in the digestive system is 3 months of daily ranitidine use and regular use over many years is especially dangerous. In fact, epidemiologists estimate that after 35 years of Zantac/ranitidine use, the risk of stomach cancer is 1 in 2. Both brand name and generic users may be affected.